Esperion Therapeutics (ESPR) Share-based Compensation (2012 - 2026)

Esperion Therapeutics' Share-based Compensation history runs 15 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• Quarterly Share-based Compensation rose 1.5% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.9 million (down 11.73% YoY) and the FY2025 annual result came in at $9.9 million, down 17.7% from the prior year.
• Share-based Compensation was $2.5 million for Q1 2026 at Esperion Therapeutics, up from $2.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $4.4 million in Q1 2022 and bottomed at $2.3 million in Q3 2025.
• A 5-year average of $3.0 million and a median of $2.9 million in 2024 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 58.91% — and 2024, when it advanced 11.44%.
• Esperion Therapeutics' Share-based Compensation stood at $3.7 million in 2022, then declined by 21.4% to $2.9 million in 2023, then dropped by 3.94% to $2.8 million in 2024, then fell by 14.9% to $2.4 million in 2025, then rose by 4.82% to $2.5 million in 2026.
• Business Quant data shows ESPR's Share-based Compensation at $2.5 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.